Methotrexate Noninferior to Prednisone in Pulmonary Sarcoidosis
By Elana Gotkine HealthDay Reporter
TUESDAY, May 20, 2025 -- For patients with pulmonary sarcoidosis, methotrexate is noninferior to prednisone with regard to the change from baseline to week 24 in the percentage of the predicted forced vital capacity (FVC), according to a study published online May 18 in the New England Journal of Medicine to coincide with the American Thoracic Society 2025 International Conference, held from May 18 to 21 in San Francisco.
Vivienne Kahlmann, M.D., from Erasmus Medical Center in Rotterdam, Netherlands, and colleagues conducted a multicenter, open-label, noninferiority trial involving patients with pulmonary sarcoidosis who had not previously received treatment. Participants were randomly assigned to receive either prednisone or methotrexate according to a prespecified treatment schedule (70 and 68 participants, respectively). The primary end point was the mean change in the percentage of the predicted FVC from baseline to week 24.
The researchers found that the unadjusted mean change in the percentage of FVC from baseline to week 24 was 6.75 and 6.11 percentage points in the prednisone and methotrexate groups, respectively. With respect to the primary end point, methotrexate was noninferior to prednisone, with an adjusted between-group difference of −1.17 percentage points (95 percent confidence interval, −4.27 to 1.93). In the two trial groups, adverse events occurred in a similar percentage of patients.
"The results of this trial show that methotrexate can be offered as an alternative for prednisone for patients with pulmonary sarcoidosis," Kahlmann said in a statement. "Some patients prioritize fast improvement of symptoms and are less afraid of side effects, while other patients may want to wait longer for treatment effects if this means they can avoid steroid toxicity."
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Paternal Prepubertal Passive Smoke Exposure Impacts Offspring Lung Function
THURSDAY, Sept. 4, 2025 -- Paternal passive smoke exposure before completing puberty may intergenerationally impair lung function in future generations, according to a study...
Risk for Mortality Higher Based on Wildfire PM2.5 Than Total PM2.5
TUESDAY, Aug. 26, 2025 -- On a global scale, relative risk for mortality associated with wildfire fine particulate matter (PM2.5) is greater than for total PM2.5, according to a...
Molgramostim Beneficial in Autoimmune Pulmonary Alveolar Proteinosis
THURSDAY, Aug. 21, 2025 -- In adults with autoimmune pulmonary alveolar proteinosis (aPAP), once-daily inhaled molgramostim, a recombinant human granulocyte-macrophage...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.